Arrowhead reported positive Phase 3 results for Redemplo (plozasiran) in severe hypertriglyceridemia, setting up a supplemental NDA filing with the FDA before year-end. The company said the drug met primary and all prespecified secondary endpoints, while also showing large reductions in median triglyceride levels versus placebo. The expanded indication could broaden Redemplo’s commercial scope beyond its prior rare-disease labeling, intensifying competition in lipid-lowering gene-silencing therapies where Ionis’ triglyceride program is already in the spotlight.